Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Pathology & Oncology Research
Published in: Pathology & Oncology Research 2/2020

01-04-2020 | Kidney Cancer | Review

The Association of Androgen Receptor Expression with Renal Cell Carcinoma Risk: a Systematic Review and Meta-Analysis

Authors: Peng Yuan, Yue Ge, Xiao Liu, Shen Wang, Zhangqun Ye, Hua Xu, Zhiqiang Chen

Published in: Pathology & Oncology Research | Issue 2/2020

Login to get access

Abstract

The relationship between androgen receptor expression and renal cell carcinoma risk remains controversial. This study is aimed to investigate the clinical significance of androgen receptor expression in renal cell carcinoma. A computerized bibliographic search of Embase, the PubMed, and Web of Science combined with manual research between 1977 and 2017 was conducted to explore the association between androgen receptor expression and clinicopathological features of renal cell carcinoma. Data were analyzed by a meta-analysis using RevMan 5.3 analysis software. Eleven retrospective studies with 1839 renal cell carcinoma cases were finally included according to the Preferred Reporting Items for Systematic Reviews and Meta-analysis guidelines. It was found that there was no significant difference between androgen receptor expression and susceptibility, pathological type, metastatic status, metastatic type (lymph or distant metastasis) and cancer-specific survival of renal cell carcinoma (P > 0.05). However, positive androgen receptor expression was demonstrated to be significantly associated with male patients, lower pathological grade, and earlier tumor stage of renal cell carcinoma (OR = 1.69, 95% CI = 1.30–2.19, P < 0.0001; OR = 2.06, 95% CI = 1.49–2.85, P < 0.0001; OR = 2.81, 95% CI = 1.30–6.12, P = 0.009; respectively). In conclusion, higher androgen receptor expression was correlated with male patients, low tumor grade and early stage of renal cell carcinoma. Based on current results, androgen receptor-inhibited target therapy for renal cell carcinoma patients may be of limited benefits and should be taken into more evaluations.
Literature
1.
2.
Campbell S, Uzzo RG, Allaf ME, Bass EB, Cadeddu JA, Chang A, Clark PE, Davis BJ, Derweesh IH, Giambarresi L, Gervais DA, Hu SL, Lane BR, Leibovich BC, Pierorazio PM (2017) Renal mass and localized renal Cancer: AUA guideline. J Urol 198:520–529PubMedCrossRef
3.
Delahunt B, Cheville JC, Martignoni G, Humphrey PA, Magi-Galluzzi C, McKenney J, Egevad L, Algaba F, Moch H, Grignon DJ, Montironi R, Srigley JR, Members of the ISUP Renal Tumor Panel (2013) The International Society of Urological Pathology (ISUP) grading system for renal cell carcinoma and other prognostic parameters. Am J Surg Pathol 37:1490–1504PubMedCrossRef
4.
Kuthi L, Jenei A, Hajdu A, Németh I, Varga Z, Bajory Z, Pajor L, Iványi B (2017) Prognostic factors for renal cell carcinoma subtypes diagnosed according to the 2016 WHO renal tumor classification: a study involving 928 patients. Pathol Oncol Res 23:689–698PubMedCrossRef
5.
He D, Li L, Zhu G, Liang L, Guan Z, Chang L, Chen Y, Yeh S, Chang C (2014) ASC-J9 suppresses renal cell carcinoma progression by targeting an androgen receptor-dependent HIF2α/VEGF signaling pathway. Cancer Res 74:4420–4430PubMedCrossRef
6.
Zhang HL, Sheng XN, Li XS, Wang HK, Chi ZH, He ZS, Ye DW, Guo J (2017) Sorafenib versus sunitinib as first-line treatment agents in Chinese patients with metastatic renal cell carcinoma: the largest multicenter retrospective analysis of survival and prognostic factors. BMC Cancer 17:16PubMedPubMedCentralCrossRef
7.
Chiarini F, Evangelisti C, McCubrey JA, Martelli AM (2015) Current treatment strategies for inhibiting mTOR in cancer. Trends Pharmacol Sci 36:124–135PubMedCrossRef
8.
Ciccarese C, Brunelli M, Montironi R, Fiorentino M, Iacovelli R, Heng D, Tortora G, Massari F (2016) The prospect of precision therapy for renal cell carcinoma. Cancer Treat Rev 49:37–44PubMedCrossRef
9.
Ravaud A, Motzer RJ, Pandha HS, George DJ, Pantuck AJ, Patel A, Chang YH, Escudier B, Donskov F, Magheli A, Carteni G, Laguerre B, Tomczak P, Breza J, Gerletti P, Lechuga M, Lin X, Martini JF, Ramaswamy K, Casey M, Staehler M, Patard JJ, S-TRAC Investigators (2016) Adjuvant Sunitinib in high-risk renal-cell carcinoma after nephrectomy. N Engl J Med 375:2246–2254PubMedCrossRef
10.
Matsumoto T, Sakari M, Okada M, Yokoyama A, Takahashi S, Kouzmenko A, Kato S (2013) The androgen receptor in health and disease. Annu Rev Physiol 75:201–224PubMedCrossRef
11.
Pihlajamaa P, Sahu B, Janne OA (2015) Determinants of receptor- and tissue-specific actions in androgen signaling. Endocr Rev 36:357–384PubMedCrossRef
12.
Bennett NC, Gardiner RA, Hooper JD, Johnson DW, Gobe GC (2010) Molecular cell biology of androgen receptor signalling. Int J Biochem Cell Biol 42:813–827PubMedCrossRef
13.
14.
Olsen JR, Azeem W, Hellem MR, Marvyin K, Hua Y, Qu Y, Li L, Lin B, Ke XIS, Øyan AM, Kalland KH (2016) Context dependent regulatory patterns of the androgen receptor and androgen receptor target genes. BMC Cancer 16:377PubMedPubMedCentralCrossRef
15.
Liang L, Li L, Tian J, Lee SO, Dang Q, Huang CK, Yeh S, Erturk E, Bushinsky D, Chang LS, He D, Chang C (2014) Androgen receptor enhances kidney stone-CaOx crystal formation via modulation of oxalate biosynthesis & oxidative stress. Mol Endocrinol 28:1291–1303PubMedPubMedCentralCrossRef
16.
Li JY, Zhou T, Gao X, Xu C, Sun Y, Peng Y, Chang Z, Zhang Y, Jiang J, Wang L, Hou J (2010) Testosterone and androgen receptor in human nephrolithiasis. J Urol 184:2360–2363PubMedCrossRef
17.
18.
Bennett NC, Rajandram R, Ng KL, Gobe GC (2014) Evaluation of steroid hormones and their receptors in development and progression of renal cell carcinoma. J Kidney Cancer VHL 1:17–25PubMedPubMedCentralCrossRef
19.
Langner C, Ratschek M, Rehak P, Schips L, Zigeuner R (2004) Steroid hormone receptor expression in renal cell carcinoma: an immunohistochemical analysis of 182 tumors. J Urol 171:611–614PubMedCrossRef
20.
Noh SJ, Kang MJ, Kim KM et al (2013) Acetylation status of P53 and the expression of DBC1, SIRT1, and androgen receptor are associated with survival in clear cell renal cell carcinoma patients. Pathology 45:574–580PubMedCrossRef
21.
Huang Q, Sun Y, Ma X, Gao Y, Li X, Niu Y, Zhang X, Chang C (2017) Androgen receptor increases hematogenous metastasis yet decreases lymphatic metastasis of renal cell carcinoma. Nat Commun 8:918PubMedPubMedCentralCrossRef
22.
Foersch S, Schindeldecker M, Keith M, Tagscherer KE, Fernandez A, Stenzel PJ, Pahernik S, Hohenfellner M, Schirmacher P, Roth W, Macher-Goeppinger S (2017) Prognostic relevance of androgen receptor expression in renal cell carcinomas. Oncotarget 8:78545–78555PubMedPubMedCentralCrossRef
23.
Vrabel M (2015) Preferred reporting items for systematic reviews and meta-analyses. Oncol Nurs Forum 42:552–554PubMedCrossRef
24.
Stang A (2010) Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 25:603–605CrossRefPubMed
25.
Ha YS, Lee GT, Modi P, Kwon YS, Ahn H, Kim WJ, Kim IY (2015) Increased expression of androgen receptor mRNA in human renal cell carcinoma cells is associated with poor prognosis in patients with localized renal cell carcinoma. J Urol 194:1441–1448PubMedCrossRef
26.
Williams EM, Higgins JP, Sangoi AR, McKenney JK, Troxell ML (2015) Androgen receptor immunohistochemistry in genitourinary neoplasms. Int Urol Nephrol 4:81–85CrossRef
27.
Zhu G, Liang L, Li L, Dang Q, Song W, Yeh S, He D, Chang C (2014) The expression and evaluation of androgen receptor in human renal cell carcinoma. Urology 83:510 e19–5510e24CrossRef
28.
Nakano E, Tada Y, Fujioka H, Matsuda M, Osafune M, Kotake T, Sato B, Takaha M, Sonoda T (1984) Hormone receptor in renal cell carcinoma and correlation with clinical response to endocrine therapy. J Urol 132:240–245PubMedCrossRef
29.
Klotzl G, Otto U, Becker H, Klosterhalfen H (1987) Determination of androgen, progestin and estrogen receptors with two different assays in renal cell carcinoma. Urol Int 42:100–104PubMedCrossRef
30.
Ronchi E, Pizzocaro G, Miodini P, Piva L, Salvioni R, Di Fronzo G (1984) Steroid hormone receptors in normal and malignant human renal tissue: relationship with progestin therapy. J Steroid Biochem 21:329–335PubMedCrossRef
31.
Concolino G, Marocchi A, Toscano V, Di Silverio F (1981) Nuclear androgen receptor as marker of responsiveness to medroxyprogesterone acetate in human renal cell carcinoma. J Steroid Biochem 15:397–402PubMedCrossRef
32.
Koryakina Y, Ta HQ, Gioeli D (2014) Androgen receptor phosphorylation: biological context and functional consequences. Endocr Relat Cancer 21:T131–T145PubMedPubMedCentralCrossRef
33.
Lin WJ, Izumi K (2014) Androgen receptor, ccl2, and epithelial-mesenchymal transition: a dangerous affair in the tumor microenvironment. Oncoimmunology 3:e27871PubMedPubMedCentralCrossRef
34.
Tonelli F, Alossaimi M, Williamson L, Tate RJ, Watson DG, Chan E, Bittman R, Pyne NJ, Pyne S (2013) The sphingosine kinase inhibitor 2-(p-hyroxyanilino)-4-(p-chlorophenyl) thiazole reduces androgen receptor expression via an oxidative stress- dependent mechanism. Br J Pharmacol 168:1497–1505PubMedPubMedCentralCrossRef
35.
Carver BS (2014) Strategies for targeting the androgen receptor axis in prostate cancer. Drug Discov Today 19:1493–1497PubMedCrossRef
36.
Miyamoto H, Yang Z, Chen YT, Ishiguro H, Uemura H, Kubota Y, Nagashima Y, Chang YJ, Hu YC, Tsai MY, Yeh S, Messing EM, Chang C (2007) Promotion of bladder cancer development and progression by androgen receptor signals. J Natl Cancer Inst 99:558–568PubMedCrossRef
37.
Chang C, Lee SO, Yeh S, Chang TM (2014) Androgen receptor (AR) differential roles in hormone-related tumors including prostate, bladder, kidney, lung, breast and liver. Oncogene 33:3225–3234PubMedCrossRef
38.
39.
Vera-Badillo FE, Templeton AJ, de Gouveia P, Diaz-Padilla I, Bedard PL, al-Mubarak M, Seruga B, Tannock IF, Ocana A, Amir E (2014) Androgen receptor expression and outcomes in early breast cancer: a systematic review and meta-analysis. J Natl Cancer Inst 106:djt319PubMedCrossRef
40.
Grogg A, Trippel M, Pfaltz K, Lädrach C, Droeser RA, Cihoric N, Salhia B, Zweifel M, Tapia C (2015) Androgen receptor status is highly conserved during tumor progression of breast cancer. BMC Cancer 15:872PubMedPubMedCentralCrossRef
41.
Gucalp A, Tolaney S, Isakoff SJ, Ingle JN, Liu MC, Carey LA, Blackwell K, Rugo H, Nabell L, Forero A, Stearns V, Doane AS, Danso M, Moynahan ME, Momen LF, Gonzalez JM, Akhtar A, Giri DD, Patil S, Feigin KN, Hudis CA, Traina TA, on behalf of the Translational Breast Cancer Research Consortium (TBCRC 011) (2013) Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic breast Cancer. Clin Cancer Res 19:5505–5512PubMedPubMedCentralCrossRef
42.
Ma WL, Lai HC, Yeh S, Cai X, Chang C (2014) Androgen receptor roles in hepatocellular carcinoma, fatty liver, cirrhosis and hepatitis. Endocr Relat Cancer 21:R165–R182PubMedPubMedCentralCrossRef
43.
Ljungberg B, Bensalah K, Canfield S, Dabestani S, Hofmann F, Hora M, Kuczyk MA, Lam T, Marconi L, Merseburger AS, Mulders P, Powles T, Staehler M, Volpe A, Bex A (2015) EAU guidelines on renal cell carcinoma: 2014 update. Eur Urol 67:913–924PubMedCrossRef
44.
Tosco L, Van Poppel H, Frea B, Gregoraci G, Joniau S (2013) Survival and impact of clinical prognostic factors in surgically treated metastatic renal cell carcinoma. Eur Urol 63:646–652PubMedCrossRef
45.
Kim SH, Kim S, Joo J, Seo HK, Joung JY, Lee KH, Chung J (2016) A retrospective study of predictive factors for unexpectedly prolonged or shortened progression-free survival and overall survival among patients with metastatic renal cell carcinoma who received first-line targeted therapy. BMC Cancer 16:577PubMedPubMedCentralCrossRef
46.
Wang K, Sun Y, Tao W, Fei X, Chang C (2017) Androgen receptor (AR) promotes clear cell renal cell carcinoma (ccRCC) migration and invasion via altering the circHIAT1/miR-195-5p/29a-3p/29c-3p/CDC42 signals. Cancer Lett 394:1–12PubMedCrossRef
47.
Zhai W, Sun Y, Guo C, Hu G, Wang M, Zheng J, Lin WY, Huang Q, Li G, Zheng J, Chang C (2017) LncRNA-SARCC suppresses renal cell carcinoma (RCC) progression via altering the androgen receptor (AR)/miRNA-143-3p signals. Cell Death Differ 24:1502–1517PubMedPubMedCentralCrossRef
48.
Czarnecka AM, Niedzwiedzka M, Porta C, Szczylik C (2016) Hormone signaling pathways as treatment targets in renal cell cancer (review). Int J Oncol 48:2221–2235PubMedCrossRef
Metadata
Title
The Association of Androgen Receptor Expression with Renal Cell Carcinoma Risk: a Systematic Review and Meta-Analysis
Authors
Peng Yuan
Yue Ge
Xiao Liu
Shen Wang
Zhangqun Ye
Hua Xu
Zhiqiang Chen
Publication date
01-04-2020
Publisher
Springer Netherlands
Published in
Pathology & Oncology Research / Issue 2/2020
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI
https://doi.org/10.1007/s12253-019-00650-z

Other articles of this Issue 2/2020

Pathology & Oncology Research 2/2020 Go to the issue

Original Article

microRNA-138-5p as a Worse Prognosis Biomarker in Pediatric, Adolescent, and Young Adult Osteosarcoma

Original Article

p63 Expression and its Relation to Epithelial Cells Proliferation in Dentigerous Cyst, Odontogenic Keratocyst, and Ameloblastoma

Letter to the Editor

Epstein-Barr Virus MicroRNAs in Nasopharyngeal Carcinoma

Original Article

Evaluation of Alpha 1-Antitrypsin for the Early Diagnosis of Colorectal Cancer

Original Article

C-X-C Chemokine Receptor Type 7 (CXCR-7) Expression in Invasive Ductal Carcinoma of Breast in Association with Clinicopathological Features

Original Article

Molecular Profile and Clinicopathologic Features of Follicular Variant Papillary Thyroid Carcinoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits